Development of 4‐Pyridoxic Acid PBPK Model to Support Biomarker‐Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease
Clinical Pharmacology & Therapeutics · 2023
DOI: 10.1002/cpt.3029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Shawn Pei Feng Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK. Hauptthemen laut MEDLINE: Pyridoxic Acid, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Monitoring endogenous biomarkers is increasingly used to evaluate transporter‐mediated drug–drug interactions (DDIs) in early drug development and may be applied to elucidate changes in transporter activity in disease. 4‐pyridoxic acid (PDA) has been identified as the most sensitive plasma endogenous biomarker of renal organic anion transporters (OAT1/3). Increase in PDA baseline concentrations was observed after administration of probenecid, a strong clinical inhibitor of OAT1/3 and also in patients with chronic kidney disease (CKD). The aim of this study was to develop and verify a physiologically‐based pharmacokinetic (PBPK) model of PDA, to predict the magnitude of probenecid DDI and predict the CKD‐related changes in PDA baseline. The PBPK model for PDA was first developed in healthy population, building on from previous population pharmacokinetic modeling, and incorporating a mechanistic kidney model to consider OAT1/3‐mediated renal secretion. Probenecid PBPK model was adapted from the Simcyp database and re‐verified to capture its dose‐dependent pharmacokinetics ( n = 9 studies). The PBPK model successfully predicted the PDA plasma concentrations, area under the curve, and renal clearance in healthy subjects at baseline and after single/multiple probenecid doses. Prospective simulations in severe CKD predicted successfully the increase in PDA plasma concentration relative to healthy (within 2‐fold of observed data) after accounting for 60% increase in fraction unbound in plasma and additional 50% decline in OAT1/3 activity beyond the decrease in glomerular filtration rate. The verified PDA PBPK model supports future robust evaluation of OAT1/3 DDI in drug development and increases our confidence in predicting exposure and renal secretion in patients with CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, Manchester, UK.
- Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen Research & Development, Beerse, Belgium.
- Bristol Myers Squibb, Princeton, New Jersey, USA.
- Certara UK Limited (Simcyp Division), Sheffield, UK.
ORCID-Profile: Shawn Pei Feng Tan, Amin Rostami-Hodjegan, Daniel Scotcher, Aleksandra Galetin
Zitieren
APA
Tan, S. P. F., Willemin, M. E., Snoeys, J., Shen, H., Rostami-Hodjegan, A., Scotcher, D., & Galetin, A. (2023). Development of 4‐Pyridoxic Acid PBPK Model to Support Biomarker‐Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3029
Vancouver
Tan SPF, Willemin ME, Snoeys J, Shen H, Rostami-Hodjegan A, Scotcher D, et al. Development of 4‐Pyridoxic Acid PBPK Model to Support Biomarker‐Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.3029
BibTeX
@article{Tan2023,
author = {Tan, Shawn Pei Feng and Willemin, Marie-Emilie and Snoeys, Jan and Shen, Hong and Rostami-Hodjegan, Amin and Scotcher, Daniel and Galetin, Aleksandra},
title = {Development of 4‐Pyridoxic Acid PBPK Model to Support Biomarker‐Informed Evaluation of OAT1/3 Inhibition and Effect of Chronic Kidney Disease},
journal = {Clinical Pharmacology & Therapeutics},
year = {2023},
doi = {10.1002/cpt.3029}
}
EUVIMED